GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » Beneish M-Score

Aquestive Therapeutics (Aquestive Therapeutics) Beneish M-Score : -1.58 (As of Apr. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.58 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Aquestive Therapeutics's Beneish M-Score or its related term are showing as below:

AQST' s Beneish M-Score Range Over the Past 10 Years
Min: -6.55   Med: -3.2   Max: 4.93
Current: -1.58

During the past 8 years, the highest Beneish M-Score of Aquestive Therapeutics was 4.93. The lowest was -6.55. And the median was -3.20.


Aquestive Therapeutics Beneish M-Score Historical Data

The historical data trend for Aquestive Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aquestive Therapeutics Beneish M-Score Chart

Aquestive Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -1.26 4.93 -4.82 -6.55 -1.58

Aquestive Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.55 -6.39 -5.37 -3.79 -1.58

Competitive Comparison of Aquestive Therapeutics's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aquestive Therapeutics's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aquestive Therapeutics's Beneish M-Score falls into.



Aquestive Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aquestive Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.6974+0.528 * 1.0089+0.404 * 0.8465+0.892 * 1.0609+0.115 * 1.6833
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.566+4.679 * -0.001881-0.327 * 0.6521
=-1.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $8.47 Mil.
Revenue was 13.206 + 13.002 + 13.241 + 11.134 = $50.58 Mil.
Gross Profit was 8.527 + 8.204 + 6.624 + 6.397 = $29.75 Mil.
Total Current Assets was $40.97 Mil.
Total Assets was $57.42 Mil.
Property, Plant and Equipment(Net PPE) was $9.74 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.35 Mil.
Selling, General, & Admin. Expense(SGA) was $31.75 Mil.
Total Current Liabilities was $18.31 Mil.
Long-Term Debt & Capital Lease Obligation was $32.91 Mil.
Net Income was -8.111 + -2.035 + -5.792 + 8.068 = $-7.87 Mil.
Non Operating Income was -1.029 + 0 + 0 + -0.353 = $-1.38 Mil.
Cash Flow from Operations was -4.942 + -2.347 + -7.907 + 8.816 = $-6.38 Mil.
Total Receivables was $4.70 Mil.
Revenue was 10.682 + 11.463 + 13.265 + 12.27 = $47.68 Mil.
Gross Profit was 5.377 + 6.838 + 8.023 + 8.056 = $28.29 Mil.
Total Current Assets was $39.89 Mil.
Total Assets was $57.07 Mil.
Property, Plant and Equipment(Net PPE) was $9.30 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.39 Mil.
Selling, General, & Admin. Expense(SGA) was $52.88 Mil.
Total Current Liabilities was $39.53 Mil.
Long-Term Debt & Capital Lease Obligation was $38.53 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(8.471 / 50.583) / (4.704 / 47.68)
=0.167467 / 0.098658
=1.6974

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(28.294 / 47.68) / (29.752 / 50.583)
=0.593414 / 0.588182
=1.0089

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (40.966 + 9.736) / 57.418) / (1 - (39.888 + 9.296) / 57.07)
=0.116967 / 0.138181
=0.8465

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=50.583 / 47.68
=1.0609

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.387 / (2.387 + 9.296)) / (1.345 / (1.345 + 9.736))
=0.204314 / 0.121379
=1.6833

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(31.75 / 50.583) / (52.879 / 47.68)
=0.627681 / 1.109039
=0.566

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((32.907 + 18.308) / 57.418) / ((38.533 + 39.528) / 57.07)
=0.891968 / 1.367811
=0.6521

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-7.87 - -1.382 - -6.38) / 57.418
=-0.001881

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aquestive Therapeutics has a M-score of -1.58 signals that the company is likely to be a manipulator.


Aquestive Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Aquestive Therapeutics (Aquestive Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
30 Technology Drive, Warren, NJ, USA, 07059
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Executives
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki officer: SVP, Research & Development C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Cassie Jung officer: SVP, Operations C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt officer: Chief Medical Officer C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris director ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd officer: SVP-Operations/Value Delivery 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender officer: SVP, General Counsel 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber officer: SVP-Chief Strategy/Dev Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel director, officer: Chief Innovation/Tech Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr officer: Interim CFO
John T. Maxwell officer: SVP-Chief Financial Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall director, officer: President and CEO 30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta director C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154

Aquestive Therapeutics (Aquestive Therapeutics) Headlines

From GuruFocus